The short version of 反相色谱 fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-03-16 and is reviewed periodically as new material appears.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Handling guidance for research quantities calls for single-use aliquots, an inert atmosphere where practical, and avoidance of repeated freeze-thaw cycles that accelerate aggregation. Certificates of analysis typically report purity by peak area, water content, counter-ion identity, and residual solvent levels. In the scientific literature the compound is usually described by its full amino acid sequence, its registry number, or its structural class rather than by any proprietary label. Reporting standards vary between journals, and reviewers increasingly request raw chromatograms alongside tabulated purity figures. Whether current purity thresholds are adequate for every experimental context is debated.
Reversed-phase high-performance liquid chromatography with ultraviolet detection is the dominant approach for peptide purity assessment, usually paired with mass spectrometry to confirm molecular mass and sequence. Peptide mapping by enzymatic digestion and tandem mass spectrometry locates modifications such as deamidation and oxidation. Quantitation in plasma matrices can be performed by LC-MS/MS after solid-phase extraction. Method validation follows general guidance on accuracy, precision, linearity, and limits of detection. Comparability of results between laboratories, when no shared reference standard is available, remains an open question.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
容器与密封系统同样参与稳定性表现。硅油涂层、胶塞材质与顶空氧含量可能改变聚集速率与氧化水平。分析结果因此需要在完整包装形式下评估，而不能仅凭原料药数据推断。法规文件通常要求同时提交批次数据与代表性容器中的稳定性趋势。
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Reversed-phase high-performance liquid chromatography is widely used to assess purity and to separate the parent peptide from related substances. Mass spectrometry confirms identity and can resolve modifications that differ by a few daltons. Size-exclusion chromatography detects dimers and higher aggregates, which are relevant to both stability and immunogenicity questions. Peptide mapping with enzymatic digestion locates specific modifications along the sequence. Circular dichroism provides a secondary-structure profile, although it gives limited information about local conformational changes.
Quality control for peptide material focuses on identity, purity, content and the profile of impurities. Common degradants include deamidated and oxidised forms, plus aggregates formed during storage or handling. Forced degradation studies under heat, light, acid and peroxide help define which conditions accelerate change and which analytical methods detect it. Limits for individual impurities are set by pharmacopoeial monographs or manufacturer specifications. How much a given impurity affects biological activity is often uncertain, and conclusions may depend on the assay used.
Solid peptide material is generally kept at reduced temperature to limit degradation. Short-term storage at 2 to 8 degrees Celsius is common, while longer archival storage at minus 20 degrees Celsius or below is typical for lyophilised powder. Vials should remain sealed and protected from light, because ultraviolet exposure can oxidise susceptible residues. Repeated freeze-thaw cycles are avoided, as they promote aggregation and loss of soluble material. Solutions are less stable than solids and are usually prepared close to the time of use.
Studies on gender and health remain limited. In the early 21st century, life expectancy in France was higher for women than men—85.3 years compared to 79.4 in 2018. However, healthy life expectancy was similar, with women at 64.5 years and men at 63.4 in 2018. Since 2004, healthy life expectancy has increased for men but remained stable for women. Historically, in Western societies, male and female health have been conceptualized differently. From Antiquity onward, the male body was viewed as the standard, while the female body was seen as a variation and more prone to illness. Diagnoses and treatment have differed depending on the patient's sex. In 17th- and 18th-century Europe, women were more often diagnosed with nervous disorders. During this period, medical and state interests in reproduction led to increased study of the female body, particularly as a reproductive body, with a focus on the uterus. New professions, such as midwifery and obstetrics, developed in this context. From the late 18th century onward, sexuality began to be medicalized. Behavioral norms were reframed in medical rather than religious terms, with differences in how male and female behavior were judged. For a prolonged period, women's bodies and intellects were considered inferior in medical discourse, contributing to gendered hierarchies. Women's health was often regarded as pathological or dysfunctional by default. Scientific research has also been shaped by gender bias.
In January 2024, Lula accepted an invitation by Egypt president Abdel Fattah el-Sisi to visit the country, which took place on 15 February. At the meeting, Brazil and Egypt signed two agreements regarding agriculture and science cooperation. Lula also met with Arab League's secretary-general Ahmed Aboul Gheit at the League's headquarters, where he called the Israeli campaign in Gaza "inhumanity and cowardice", urging "the collective punishment" of Palestinians by Israel to stop, thus calling for a ceasefire, and all the hostages taken by Hamas to be unconditionally and immediately released. Lula equally defended the international recognition of the Palestinian state, with East Jerusalem as its capital.
=== No development reported === AD-6626 – aldehyde dehydrogenase 2 (ALDH2) inhibitor – alcoholism AM-6527 (AM6527) – cannabinoid CB1 receptor antagonist – substance-related disorders Amitifadine (DOV-21947; EB-1010) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – alcoholism, opioid-related disorders, smoking withdrawal, substance-related disorders Arbaclofen extended release – GABAB receptor agonist – opioid-related disorders BMB-101 – serotonin 5-HT2 receptor agonist – opioid-related disorders Bupropion/mecamylamine (INT-0003; QuitPak) – combination of bupropion (norepinephrine–dopamine reuptake inhibitor (NDRI), nicotinic acetylcholine receptor negative allosteric modulator) and mecamylamine (non-selective nicotinic acetylcholine receptor antagonist) – smoking withdrawal Cannabidiol (CBD; cannabidiol transderma/topical gel/patch; Zygel; ZYN-002) – cannabinoid/various actions – alcoholism, substance-related disorders CM-1212 – undefined mechanism of action – alcoholism, substance-related disorders CPP-115 – GABA transaminase (GABA-T) inhibitor – substance-related disorders CT-044 analogues - CERSCI Therapeutics – reactive oxygen species (ROS) inhibitors (CT-044 analogues) – opioid-related disorders CX-717 (CX717) – AMPA receptor positive allosteric modulator (ampakine) – substance-related disorders Cyproheptadine/prazosin (KT-110; Periactine/Alpress) – combination of cyproheptadine (various actions) and prazosin (α1-adrenergic receptor antagonist) – substance-related disorders DCR-AUD (DCR-A1203; NN-6020) – aldehyde dehydrogenase 2 (ALDH2) inhibitor, RNA interference – alcoholism Dimethyltryptamine (DMT; EBRX-101) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – smoking withdrawal GLWL-01 – ghrelin O-acyltransferase (GOAT) inhibitor – alcoholism GSK-598809 (GSK598809) – dopamine D3 receptor antagonist – smoking withdrawal, substance-related disorders GSK-1521498 – μ-opioid receptor inverse agonist – cocaine-related disorders GTS-21 (DMXB-A; DMBX-anabaseine) – nicotinic acetylcholine receptor agonist – smoking withdrawal Icalcaprant (ABBV-1354; CVL-354) – κ-opioid receptor antagonist – substance-related disorders Levodopa (CVT-301; CXG-89; Inbrija) – dopamine precursor (non-selective dopamine receptor agonist) – smoking withdrawal Mazindol controlled release (NLS-0; NLS-1; NLS-10; NLS-13; NLS-2; Nolazol; Quilience) – serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI) – opioid-related disorders Midomafetamine (MDMA; ecstasy) – serotonin–norepinephrine–dopamine releasing agent (SNDRA), serotonin 5-HT2 receptor agonist, and entactogen – substance-related disorders Mifepristone (C-1073; Corlux; Corluxin; Korlym; Mifegyne; Mifeprex; RU-38486; RU-486) – glucocorticoid, progesterone, and androgen receptor antagonist – smoking withdrawal Modafinil oral (ASB) – atypical dopamine reuptake inhibitor (DRI) – cocaine-related disorders Naloxone nasal spray (-12; LT-20; LT-21; LT-22; Naloxon B; Narcan Nasal Spray; OPNT-001) – μ-opioid receptor antagonist – cocaine-related disorders, substance-related disorders Nalmefene implant (nalmefene six-month implant) – μ-opioid receptor antagonist, κ-opioid receptor weak partial agonist – opioid-related disorders Naloxone buccal/intransal gel (Exonal) – opioid receptor antagonist – opioid-related disorders Nicotine abuse vaccine (Niccine) – nicotinic acetylcholine receptor agonist – smoking withdrawal Nicotine/cannabidiol chewing gum (nicotine/CBD; CVSI-007) – combination of nicotine (nicotinic acetylcholine receptor agonist) and cannabidiol (CBD) (cannabinoid/various actions) – smoking withdrawal Noribogaine derived therapeutic – various actions (noribogaine derivative) – opioid-related disorders OMS-405 (OMS405) – PPARγ agonist – alcoholism Ondansetron (AD-04) – serotonin 5-HT3 receptor antagonist – opioid-related disorders, smoking withdrawal Ondansetron/topiramate (AD-01; AD/TO-01) – combination of ondansetron (serotonin 5-HT3 receptor antagonist) and topiramate (various actions) – alcoholism Ondelopran (LY-2196044; Odelepan; Odelepran; OpRA) – opioid receptor antagonist – alcoholism OPNT-005 (OPNT005; adjuvanted heroin analogue vaccine; diamorphine analogue vaccine; heroin vaccine) – immunostimulant (vaccine against heroin) – heroin-related disorders PF-5402536 (NIC7-001; PF-5402536) – immunostimulant (smoking vaccine) – smoking withdrawal Pomaglumetad methionil (DB103; LY-2140023; LY-2812223; LY-404039 prodrug) – metabotropic glutamate mGlu2 and mGlu3 receptor receptor agonist (pomaglumetad prodrug) – substance-related disorders PPL-103 – μ-opioid receptor agonist, δ-opioid receptor agonist, κ-opioid receptor agonist – substance-related disorders Pregnenolone methyl ether (3β-methoxypregnenolone; MAP-4343) – microtubule-associated protein (MAP) stimulant and tubulin polymerization promoter – substance-related disorders Psilocybin (MYCO-001; MYCO-003) – non-selective serotonin receptor agonist, serotonin 5-HT2A receptor agonist, and serotonergic psychedelic – substance-related disorders PT-150 (PT150; ORG-34517; SCH-900636) – androgen and glucocorticoid receptor antagonist – alcoholism Research programme: alcoholism therapeutics - ADial Pharmaceuticals – various actions – alcoholism Research programme: allosteric modulators - Addex Therapeutics – various actions – substance-related disorders Research programme: GPCR modulators - Nxera Pharma – various actions – cocaine-related disorders, substance-related disorders Research programme: nociceptin receptor agonists - Astraea Therapeutics – nociceptin receptor agonist, opioid receptor agonist – alcoholism, substance-related disorders Research programme: smoking cessation therapies - Ophidion – smoking withdrawal – nicotinic acetylcholine receptor agonists Research programme: tryptamine based therapeutics - PsyBio Therapeutics – serotonin 5-HT2A receptor agonists – substance-related disorders RTI-598929 – μ-opioid receptor antagonist and κ-opioid receptor antagonist – heroin-related disorders Saracatinib (AZD-0530) – Src-family kinase inhibitor – alcoholism SBP-9330 – metabotropic glutamate mGlu2 receptor modulator – smoking withdrawal SEL-068 (tSVP; immunomodulatory nanoparticle vaccine for smoking cessation) – immunomodulator (smoking vaccine) – smoking withdrawal Serdexmethylphenidate (KP-484; KP-1077; KP-1077H; KP-1077IH; KP-1077N; KP-879) – norepinephrine–dopamine reuptake inhibitor (NDRI) (dexmethylphenidate prodrug) – substance-related disorders TRV-734 (TRV734) – μ-opioid receptor biased agonist – opioid-related disorders VDM-001 – opioid receptor antagonist – alcoholism, opioid-related disorders Zolunicant (18-methoxycoronaridine; 18-MC; MM-110) – α3β4 nicotinic acetylcholine receptor antagonist – substance-related disorders
==== Cooperation with capitalist law ==== Despite calling for the establishment of socialist political parties, Socialist Studies believes that such parties should not engage in political action which requires use of or active cooperation with what they call "capitalist law" or "bourgeois legislation". This arises from their interpretation of Clause 8 of their Declaration of Principles. That clause states that "Socialist Studies [...] enters the field of political action". The group interprets this as specifically excluding "legal or moral action" and as "overrid[ing] any other consideration". In light of this, they accuse the SPGB of being capitalist collaborators for having registered with the Electoral Commission, which is a legal requirement to contest elections in the United Kingdom. Nonetheless, members of the group had previously registered as candidates for parliamentary and council elections when they were members of the SPGB and the group itself eventually registered with the Electoral Commission. The group as a whole has also occasionally appealed to the state's legal institutions, such as their 1994 lawsuit against the Britannia Building Society. They have also accused others of "criminal libel" and have repeatedly indicated that they are prepared to sue, if necessary.
Kashmiri is the most widely spoken language in Jammu and Kashmir, spoken by 53% of the population. Dogri is spoken by 20.5% and Gujari by 9.5% of the total population. Other main languages include Pahari spoken by 7.9%, Hindi by 2.3% and Punjabi by 1.8%. Kashmiri is primarily spoken in the Kashmir Valley and in the upper reaches of the Chenab Valley, with a sizeable number of speakers in Jammu City. Dogri, is spoken throughout the plains areas of Jammu division, as well as in parts of the hills. In Poonch, Rajouri and Ganderbal districts and In the Pir Panjal Range, bordering Pakistan-administered Kashmir, the main language is Gujari spoken by the Gujjars as well as Pahari-Pothwari. In the eastern hills of Jammu division are spoken various Western Pahari languages such as Siraji and Bhaderwahi, which merge with the dialects of western Himachal Pradesh. Urdu is also widely understood and spoken, particularly in the Kashmir region where it acts as the lingua franca alongside Kashmiri and also serves as a medium of instruction along with English, while Hindi is taught and understood in the southern areas of Jammu.
Sources: en.wikipedia.org
Both ROS-elevating and ROS-eliminating strategies have been developed with the former being predominantly used. Cancer cells with elevated ROS levels depend heavily on the antioxidant defense system. ROS-elevating drugs further increase cellular ROS stress level, either by direct ROS-generation (e.g. motexafin gadolinium, elesclomol) or by agents that abrogate the inherent antioxidant system such as SOD inhibitor (e.g. ATN-224, 2-methoxyestradiol) and GSH inhibitor (e.g. PEITC, buthionine sulfoximine (BSO)). The result is an overall increase in endogenous ROS, which when above a cellular tolerability threshold, may induce cell death. On the other hand, normal cells appear to have, under lower basal stress and reserve, a higher capacity to cope with additional ROS-generating insults than cancer cells do. Therefore, the elevation of ROS in all cells can be used to achieve the selective killing of cancer cells. James Watson and others have proposed that lack of intracellular ROS due to a lack of physical exercise may contribute to the malignant progression of cancer, because spikes of ROS are needed to correctly fold proteins in the endoplasmic reticulum and low ROS levels may thus aspecifically hamper the formation of tumor suppressor proteins. Since physical exercise induces temporary spikes of ROS, this may explain why physical exercise is beneficial for cancer patient prognosis.
== Occurrence == Acetamide has been detected near the center of the Milky Way galaxy. This finding is potentially significant because acetamide has an amide bond, similar to the essential bond between amino acids in proteins. This finding lends support to the theory that organic molecules that can lead to life (as we know it on Earth) can form in space. On 30 July 2015, scientists reported that upon the first touchdown of the Philae lander on comet 67/P's surface, measurements by the COSAC and Ptolemy instruments revealed sixteen organic compounds, four of which – acetamide, acetone, methyl isocyanate, and propionaldehyde – were seen for the first time on a comet. In addition, acetamide is found infrequently on burning coal dumps, as a mineral of the same name.
=== Technology === When considering food storage and preservation, the technologies of modified atmosphere and controlled atmosphere are widely used for the storage and packing of several types of foods. They offer several advantages such as delay of ripening and senescence of horticultural commodities, control of some biological processes such as rancidity, insects, bacteria and decay, among others. Controlled atmosphere (CA) storage refers to atmospheres that are different than normal air and strictly controlled at all times. This type of storage manipulates the CO2 and O2 levels within airtight stores of containers. Modified atmosphere (MA) storage refers to any atmosphere different from normal air, typically made by mixing CO2, O2, and N2.
== Pharmacology == Like ALD-52 (1A-LSD), 1P-LSD is believed to act as a prodrug for LSD via hydrolysis of the propionyl group. When 1P-LSD is incubated in human serum or liver cells, administered intravenously to rats, or administered either orally or intravenously to human subjects, high levels of LSD and relatively low levels of 1P-LSD are quickly detected, demonstrating that 1P-LSD is rapidly hydrolyzed into LSD in vivo following ingestion. Indeed, following intravenous administration in humans 1P-LSD is detectable in serum for no longer than 4 hours, after which it is completely converted to LSD. These findings are supported by the similar duration and behavioral effects of 1P-LSD and LSD in both animal and human experiments.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Purity is commonly expressed as the percentage of the main peak relative to all integrated peaks in a reversed-phase chromatogram. Related substances and counter-ions are reported separately. Values obtained with different detectors are not always directly comparable.